Correction to: JAK Inhibitors for Atopic Dermatitis: An Update

被引：0
|
作者：
Helen He
Emma Guttman-Yassky
机构：
[1] Icahn School of Medicine at Mount Sinai,Department of Dermatology and the Immunology Institute
[2] The Rockefeller University,Laboratory for Investigative Dermatology
来源：
American Journal of Clinical Dermatology | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Page 7, Table 1, ASN002 row. The cell entry in column 4, “Manufacturer”, which previously read:
引用
收藏
页码：193 / 193
相关论文
共 50 条
  • [41] Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis
    Wood, Hannah
    Chandler, Antoinette
    Nezamololama, Novin
    Papp, Kim
    Gooderham, Melinda J.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (06) : 746 - 754
  • [42] The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis
    Miao, Mengyu
    Ma, Lei
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 1869 - 1877
  • [43] Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
    Kim, Richard W.
    Lam, Megan
    Abuabara, Katrina
    Simpson, Eric L.
    Drucker, Aaron M.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (02) : 179 - 193
  • [44] Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
    Sandra Ferreira
    Emma Guttman-Yassky
    Tiago Torres
    American Journal of Clinical Dermatology, 2020, 21 : 783 - 798
  • [45] The efficacy of JAK inhibitors in adult eosinophilic colitis with atopic dermatitis; four cases report
    Matsumto, Hiroshi
    Sasahira, Momoyo
    Fujimoto, Yasuhito
    Yo, Shogen
    Shiotani, Akiko
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2025, 18 (01) : 100 - 106
  • [46] JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
    Szalus, Krzysztof
    Trzeciak, Magdalena
    Nowicki, Roman J.
    MICROORGANISMS, 2020, 8 (11) : 1 - 14
  • [47] Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
    van Der Gang, Lian F.
    Atash, Keneshka
    Zuithoff, Nicolaas P. A.
    Haeck, Inge
    Boesjes, Celeste M.
    Bacos-Cosma, Octavian I.
    Loman, Laura
    Kamsteeg, Marijke
    Stadhouders-Keet, Simone
    Oosting, Albert J.
    van Lynden-van Nes, Anneke M. T.
    Politiek, Klaziena
    Gostynksi, Antoni
    Berntsen-Zandbergen, Lisette
    Christoffers, Wianda A.
    Flinterman, Annebeth
    Touwslager, Wouter R. H.
    Velstra, Berit
    Stewart, Shiarra M.
    van Erp, Francine C.
    de Graaf, Marlies
    Schuttelaar, Marie-Louise A.
    de Bruin-Weller, Marjolein S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
  • [48] Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
    Ferreira, Sandra
    Guttman-Yassky, Emma
    Torres, Tiago
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (06) : 783 - 798
  • [49] Update on safety of topical calcineurin inhibitors in atopic dermatitis: Recommendations and current evidence
    Anderson, L.
    Su, J.
    Varigos, G.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 36 - 36
  • [50] Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry
    Simpson, Eric
    Fenske, Christian
    Li, Alvin
    Dawson, Zach
    Maldonado, Yolanda Munoz
    Ho, Kaylee
    Callahan, Kayla
    Gold, Linda Stein
    Desai, Seemal
    Golant, Alexandra
    DiRuggiero, Douglas
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
12345